2026 Avi Ashkenazi: Biology and Biochemistry Researcher – H-Index, Publications & Awards

D-Index & Metrics

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Biology and Biochemistry	110	958	848	595	515	336	62717

Discipline name

D-Index

World Ranking

Current World Ranking

National Ranking

Current National Ranking

Publications

Citations

Biology and Biochemistry

110

958

848

595

515

336

62717

Biology and Biochemistry

D-Index

110

Citations

62717

World Ranking

958

National Ranking

595

Overview

Avi Ashkenazi is affiliated with MIT in the United States and has a research focus centered on molecular biology and its intersections with medicine. Their work spans multiple topics, particularly emphasizing cellular stress responses and related disease mechanisms.

The primary fields of study for Avi Ashkenazi include biochemistry, genetics, and molecular biology, with significant contributions also made in medicine. The scientist's research is further specialized within subfields such as cell biology, molecular biology, epidemiology, immunology, and surgery.

Core topics addressed in their research include:

Endoplasmic Reticulum Stress and Disease
Autophagy in Disease and Therapy
Cellular transport and secretion
RNA regulation and disease
RNA Research and Splicing
Pancreatic function and diabetes
Ubiquitin and proteasome pathways

Avi Ashkenazi has published extensively, with noteworthy contributions to academic journals and venues including:

bioRxiv (Cold Spring Harbor Laboratory)
Nature Communications
eLife
PLoS Biology
Cancer Research

Some of their recent papers include:

"Misfolded proteins bind and activate death receptor 5 to trigger apoptosis during unresolved endoplasmic reticulum stress," 2020, eLife
"IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment," 2020, Cancer Research
"Endoplasmic reticulum stress activates human IRE1α through reversible assembly of inactive dimers into small oligomers," 2022, eLife
"Decoding non-canonical mRNA decay by the endoplasmic-reticulum stress sensor IRE1α," 2021, Nature Communications
"Homeostasis control in health and disease by the unfolded protein response," 2024, Nature Reviews Molecular Cell Biology

Collaboration has been a notable aspect of Avi Ashkenazi's scientific output. Frequent coauthors include:

Scot A. Marsters
Peter Walter
Joachim Rudolph
Zora Modrušan
Adrien Le Thomas

Best Publications

Death receptors: signaling and modulation

Avi Ashkenazi;Vishva M. Dixit

8445
Citations
Safety and antitumor activity of recombinant soluble Apo2 ligand

Avi Ashkenazi;Roger C. Pai;Sharon Fong;Susan Leung

2881
Citations
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family *

Robert M. Pitti;Scot A. Marsters;Siegfried Ruppert;Christopher J. Donahue

2471
Citations
Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors

James P. Sheridan;Scot A. Marsters;Robert M. Pitti;Austin Gurney

2278
Citations
Targeting death and decoy receptors of the tumour-necrosis factor superfamily

Avi Ashkenazi

1925
Citations
Apoptosis control by death and decoy receptors

Avi Ashkenazi;Vishva M Dixit

1781
Citations
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

Frank C Kischkel;David A Lawrence;Anan Chuntharapai;Peter Schow

1281
Citations
Apo2L/TRAIL and its death and decoy receptors.

H N LeBlanc;A Ashkenazi

1143
Citations
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer

Robert M. Pitti;Scot A. Marsters;David A. Lawrence;Margaret Roy

1128
Citations
Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors.

E G Peralta;A Ashkenazi;J W Winslow;D H Smith

1018
Citations
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

David Lawrence;Zahra Shahrokh;Scot Marsters;Kirsten Achilles

909
Citations
A novel receptor for Apo2L/TRAIL contains a truncated death domain

S.A. Marsters;J.P. Sheridan;R.M. Pitti;A. Huang

886
Citations
Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes

Ernest G. Peralta;Avi Ashkenazi;Avi Ashkenazi;John W. Winslow;J. Ramachandran;J. Ramachandran

847
Citations
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

Avi Ashkenazi;Wayne J. Fairbrother;Joel D. Leverson;Andrew J. Souers

797
Citations
Pharmacological brake-release of mRNA translation enhances cognitive memory

Carmela Sidrauski;Diego Acosta-Alvear;Arkady Khoutorsky;Punitha Vedantham

749
Citations
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy.

Alexandru Almasan;Avi Ashkenazi

726
Citations
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL

Klaus W Wagner;Elizabeth A Punnoose;Thomas Januario;David A Lawrence

721
Citations
Cullin3-Based Polyubiquitination and p62-Dependent Aggregation of Caspase-8 Mediate Extrinsic Apoptosis Signaling

Zhaoyu Jin;Yun Li;Robert Pitti;David Lawrence

713
Citations
Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8.

Frank C. Kischkel;David A. Lawrence;Antoine Tinel;Heidi LeBlanc

708
Citations
Death receptor signal transducers: nodes of coordination in immune signaling networks.

Nicholas S Wilson;Vishva Dixit;Avi Ashkenazi

689
Citations